Hemolink delivers significant oxygen, says study:
This article was originally published in Clinica
The oxygen-carrying characteristics of Hemosol's blood substitute, Hemolink, are similar to those of fresh blood, according to the results of an in vitro study. The speed by which Hemolink retrieved and delivered oxygen was fast and appeared to coincide with the normal blood process, said Canadian researchers, who presented the findings at last week's American Society of Hematology meeting in Orlando, Florida. "This study is further confirmation of Hemolink's ability to retrieve oxygen in the lungs and immediately, efficiently and safely deliver it to the body's organs to treat acute anaemia," added Toronto-based Hemosol.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.